Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
First Tracks BiotherapeuticsMEX:TRAX 12 Debt-to-Equity is 0.04 as of Dec. 2024, which is at its 10-year median of 0.04. GuruFocus rates MEX:TRAX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 956 Biotechnology companies, First Tracks Biotherapeutics ranks better than 75% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for First Tracks Biotherapeutics's Debt-to-Equity or its related term are showing as below:
MEX:TRAX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.04 Max: 0.04
Current: 0.04
During the past 2 years, the highest Debt-to-Equity Ratio of First Tracks Biotherapeutics was 0.04. The lowest was 0.04. And the median was 0.04.
MEX:TRAX's Debt-to-Equity is ranked better than 75% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs MEX:TRAX: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
First Tracks Biotherapeutics Debt-to-Equity Related Terms
First Tracks Biotherapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics Debt-to-Equity Chart
First Tracks Biotherapeutics Annual Data
Trend
Dec23
Dec24
Debt-to-Equity
0.04
0.04
First Tracks Biotherapeutics Semi-Annual Data
Dec23
Dec24
Debt-to-Equity
0.04
0.04
MEX:TRAX vs AVLN, IMTX, ARDX: Debt-to-Equity Comparison
For the Biotechnology subindustry, First Tracks Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
First Tracks Biotherapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where First Tracks Biotherapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
First Tracks Biotherapeutics (MEX:TRAX) has a Debt-to-Equity of 0.04 as of Dec. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on First Tracks Biotherapeutics and its competitors. This is near median its historical median of 0.04. Over the past decade, First Tracks Biotherapeutics' Debt-to-Equity has ranged from 0.04 to 0.04. According to the industry distribution chart, First Tracks Biotherapeutics ranks #239 out of 956 companies in the Biotechnology industry, placing it in the top 25%.
Is First Tracks Biotherapeutics' Debt-to-Equity too high?
First Tracks Biotherapeutics' current Debt-to-Equity of 0.04 is near median its 10-year median of 0.04. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.04. The Biotechnology industry median Debt-to-Equity is 0.16. First Tracks Biotherapeutics' value of 0.04 is 75% below this industry median. Based on the distribution chart, First Tracks Biotherapeutics ranks #239 out of 956 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Debt-to-Equity compare to AVLN and IMTX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #239 out of 956 companies for Debt-to-Equity. This places First Tracks Biotherapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. First Tracks Biotherapeutics' value of 0.04 is 75% below this benchmark. Historically, First Tracks Biotherapeutics' own Debt-to-Equity has ranged from 0.04 to 0.04 over the past decade. While the company's 10-year median is 0.04 vs. the industry median of 0.16, First Tracks Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. First Tracks Biotherapeutics's current Debt-to-Equity of 0.04 is 75% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on First Tracks Biotherapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. First Tracks Biotherapeutics's current Debt-to-Equity is 0.04, which is near median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (MEX:TRAX) has a current Debt-to-Equity of 0.04. The current Debt-to-Equity is 0.04, which is near median its 10-year median of 0.04 and 75% below the Biotechnology industry median of 0.16. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For First Tracks Biotherapeutics (MEX:TRAX), the current Debt-to-Equity is 0.04 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score
Get the complete analysis for MEX:TRAX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TRAX has been successfully added to your 
